이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Vicore Pharma Holding 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ahmed Mousa

최고 경영자

SEK 6.3m

총 보상

CEO 급여 비율	23.5%
CEO 임기	1.5yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.1yrs
이사회 평균 재임 기간	1.2yrs

최근 관리 업데이트

Recent updates

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Feb 10

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Sep 21

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

May 25

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Jan 10

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Nov 13

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Jul 26

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Mar 03

What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

Jan 11

CEO 보상 분석

Ahmed Mousa 의 보수는 Vicore Pharma Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 6m	SEK 1m	-SEK 311m

보상 대 시장: Ahmed 의 총 보상 ($USD 600.61K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 475.79K ).

보상과 수익: Ahmed 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Ahmed Mousa (39 yo)

1.5yrs

테뉴어

SEK 6,339,074

보상

Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ahmed Mousa	Chief Executive Officer	1.5yrs	SEK 6.34m	데이터 없음
Hans Jeppsson	Chief Financial Officer	7.1yrs	데이터 없음	0.0045% SEK 100.1k
Mikael Nygård	Vice President of Operations & Corporate Strategy	less than a year	데이터 없음	0.0036% SEK 80.9k
Johan Raud	Chief Scientific Officer	6.5yrs	데이터 없음	0.21% SEK 4.8m
Nina Carlen	Chief Administrative Officer	15.5yrs	데이터 없음	0.022% SEK 490.8k
Jessica Shull	Head of Digital Therapeutics & Director of Digital Health	3.2yrs	데이터 없음	데이터 없음
Asa Magnusson	Chief Engagement & Commercial Officer	2.8yrs	데이터 없음	데이터 없음
Bertil Lindmark	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Sophie Bertilsson	Interim Head of CMC	less than a year	데이터 없음	데이터 없음
Jimmie Hofman	Vice President of Business Development	less than a year	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: VICO 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jacob Gunterberg	Director	no data	SEK 886.00k	0.0057% SEK 128.4k
Michael Buschle	Director	1.2yrs	SEK 405.00k	데이터 없음
Ann Barbier	Director	less than a year	데이터 없음	데이터 없음
Yasir Al-Wakeel	Director	less than a year	데이터 없음	데이터 없음
Hans J. G. C. Schikan	Independent Chairman	5.9yrs	SEK 450.00k	0.0036% SEK 80.2k
Elisabeth Bjork	Director	1.2yrs	SEK 405.00k	데이터 없음
Heidi Hunter	Independent Director	4.2yrs	SEK 519.00k	0.0045% SEK 100.1k

1.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: VICO 의 이사회는 경험(평균 재직 기간 1.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Vicore Pharma Holding 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Recent updates

New minor risk - Share price stability

Less than half of directors are independent

Consensus EPS estimates fall by 20%

Vicore Pharma Holding AB (Publ) Announces Board Appointments

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Price target decreased by 13% to kr61.50

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

Consensus revenue estimates increase by 3,123,023%

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Price target decreased to kr74.67

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Now 20% undervalued after recent price drop

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Consensus forecasts updated

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Consensus forecasts updated

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Price target decreased to kr80.40

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Independent Director recently bought kr87k worth of stock

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Price target increased to kr93.50

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Price target decreased to kr55.00

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Price target increased to kr72.00

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

New 90-day high: kr28.70

Price target raised to kr54.00

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: kr18.40

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021